XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency
XORTX Therapeutics Inc. ("XORTX" or the "Company") NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and
XORTX stopped working with the company that helps talk to investors and the public about the business. This might mean they're saving money or changing their plans, so pay attention to what they do next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.